These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 22434108

  • 21. The effects of RAMPs upon cell signalling.
    Routledge SJ, Ladds G, Poyner DR.
    Mol Cell Endocrinol; 2017 Jul 05; 449():12-20. PubMed ID: 28390954
    [Abstract] [Full Text] [Related]

  • 22. Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors.
    Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD, Christopoulos A, Sexton PM.
    Endocrinology; 2008 Nov 05; 149(11):5423-31. PubMed ID: 18599553
    [Abstract] [Full Text] [Related]

  • 23. Regulation of calcium sensing receptor trafficking by RAMPs.
    Bouschet T, Martin S, Henley JM.
    Adv Exp Med Biol; 2012 Nov 05; 744():39-48. PubMed ID: 22434106
    [Abstract] [Full Text] [Related]

  • 24. An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology.
    J Gingell J, Simms J, Barwell J, Poyner DR, Watkins HA, Pioszak AA, Sexton PM, Hay DL.
    Cell Discov; 2016 Nov 05; 2():16012. PubMed ID: 27462459
    [Abstract] [Full Text] [Related]

  • 25. Regulation of GPCR trafficking by RAMPs.
    Bomberger JM, Parameswaran N, Spielman WS.
    Adv Exp Med Biol; 2012 Nov 05; 744():25-37. PubMed ID: 22434105
    [Abstract] [Full Text] [Related]

  • 26. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product.
    Zumpe ET, Tilakaratne N, Fraser NJ, Christopoulos G, Foord SM, Sexton PM.
    Biochem Biophys Res Commun; 2000 Jan 07; 267(1):368-72. PubMed ID: 10623626
    [Abstract] [Full Text] [Related]

  • 27. A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors.
    Conner AC, Hay DL, Simms J, Howitt SG, Schindler M, Smith DM, Wheatley M, Poyner DR.
    Mol Pharmacol; 2005 Jan 07; 67(1):20-31. PubMed ID: 15615699
    [Abstract] [Full Text] [Related]

  • 28. A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1.
    Bühlmann N, Leuthäuser K, Muff R, Fischer JA, Born W.
    Endocrinology; 1999 Jun 07; 140(6):2883-90. PubMed ID: 10342881
    [Abstract] [Full Text] [Related]

  • 29. A critical role for the short intracellular C terminus in receptor activity-modifying protein function.
    Udawela M, Christopoulos G, Morfis M, Christopoulos A, Ye S, Tilakaratne N, Sexton PM.
    Mol Pharmacol; 2006 Nov 07; 70(5):1750-60. PubMed ID: 16912219
    [Abstract] [Full Text] [Related]

  • 30. RAMPs and CGRP receptors.
    Barwell J, Wootten D, Simms J, Hay DL, Poyner DR.
    Adv Exp Med Biol; 2012 Nov 07; 744():13-24. PubMed ID: 22434104
    [Abstract] [Full Text] [Related]

  • 31. Calcitonin receptor-like receptor (CLR) influences posttranslational events of receptor activity-modifying proteins (RAMPs).
    Nag K, Sultana N, Hirose S.
    Biochem Biophys Res Commun; 2012 Feb 24; 418(4):824-9. PubMed ID: 22321396
    [Abstract] [Full Text] [Related]

  • 32. Itch receptor MRGPRX4 interacts with the receptor activity-modifying proteins.
    Kotliar IB, Ceraudo E, Kemelmakher-Liben K, Oren DA, Lorenzen E, Dodig-Crnković T, Horioka-Duplix M, Huber T, Schwenk JM, Sakmar TP.
    J Biol Chem; 2023 May 24; 299(5):104664. PubMed ID: 37003505
    [Abstract] [Full Text] [Related]

  • 33. Regulation of RAMP expression in diseases.
    Jacob A, Wu R, Wang P.
    Adv Exp Med Biol; 2012 May 24; 744():87-103. PubMed ID: 22434110
    [Abstract] [Full Text] [Related]

  • 34. Flow cytometric analysis of the calcitonin receptor-like receptor domains responsible for cell-surface translocation of receptor activity-modifying proteins.
    Kuwasako K, Kitamura K, Nagata S, Kato J.
    Biochem Biophys Res Commun; 2009 Jun 26; 384(2):249-54. PubMed ID: 19394311
    [Abstract] [Full Text] [Related]

  • 35. RAMPs: The past, present and future.
    Parameswaran N, Spielman WS.
    Trends Biochem Sci; 2006 Nov 26; 31(11):631-8. PubMed ID: 17010614
    [Abstract] [Full Text] [Related]

  • 36. Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
    Kuwasako K, Cao YN, Nagoshi Y, Tsuruda T, Kitamura K, Eto T.
    Mol Pharmacol; 2004 Jan 26; 65(1):207-13. PubMed ID: 14722252
    [Abstract] [Full Text] [Related]

  • 37. Introduction to RAMPs.
    Parameswaran N, Spielman WS.
    Adv Exp Med Biol; 2012 Jan 26; 744():1-11. PubMed ID: 22434103
    [Abstract] [Full Text] [Related]

  • 38. Expanding the GPCR-RAMP interactome.
    Kotliar IB, Bendes A, Dahl L, Chen Y, Saarinen M, Ceraudo E, Dodig-Crnković T, Uhle'n M, Svenningsson P, Schwenk JM, Sakmar TP.
    bioRxiv; 2023 Nov 23. PubMed ID: 38045268
    [Abstract] [Full Text] [Related]

  • 39. Receptor autoradiography as mean to explore the possible functional relevance of neuropeptides: focus on new agonists and antagonists to study natriuretic peptides, neuropeptide Y and calcitonin gene-related peptides.
    Dumont Y, Chabot JG, Quirion R.
    Peptides; 2004 Mar 23; 25(3):365-91. PubMed ID: 15134861
    [Abstract] [Full Text] [Related]

  • 40. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor.
    Salvatore CA, Mallee JJ, Bell IM, Zartman CB, Williams TM, Koblan KS, Kane SA.
    Biochemistry; 2006 Feb 14; 45(6):1881-7. PubMed ID: 16460034
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.